Bacteremia Clinical Trial
Official title:
Epidemiology, Outcomes, and Costs Associated With Gram Negative Bacteremia
This study examines the clinical outcomes and healthcare costs associated with gram negative bacteremia at Duke University Medical Center from 2002-2015.
Specific Aim 1: Define the clinical impact of gram negative bacterial (GNB) bloodstream
infections (BSI). In this objective, the investigators will describe the prevalence, source
of bacteremia, and location of acquisition (i.e., community-acquired, healthcare-associated,
hospital-acquired) of GNB BSI. The investigators will also examine the outcomes associated
with GNB BSI including length of hospital stay, length of ICU stay, in-house mortality, and
hospital costs.
Specific Aim 2: Describe antibiotic resistance patterns in GNB BSI, and explore associations
between antibiotic resistance and clinical and economic outcomes. In this objective, the
investigators will describe the prevalence and antibiotic susceptibility profiles of
multidrug resistant phenotypes including MDR bacteria, which are defined by resistance to
three or more drug classes, ESBL-producers, and CRE. The investigators will examine the
differences in mortality, resource use (length of hospital stay, length of ICU stay), and
direct medical costs between cases with and without antibiotic resistance.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03894046 -
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
|
Phase 3 | |
| Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
| Withdrawn |
NCT02543957 -
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
|
||
| Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
| Completed |
NCT01410578 -
The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO
|
N/A | |
| Completed |
NCT00609375 -
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
|
Phase 4 | |
| Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
| Completed |
NCT00177736 -
Pharmacodynamic Parameters of Two Different Doses of Cefepime
|
Phase 4 | |
| Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
| Completed |
NCT00571259 -
Prophylactic Antimicrobial Catheter Lock
|
Phase 4 | |
| Completed |
NCT00027248 -
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
|
Phase 3 | |
| Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
| Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
| Completed |
NCT03148769 -
Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors
|
||
| Completed |
NCT02536352 -
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being
|
Early Phase 1 | |
| Completed |
NCT02869191 -
Blood Cultures's Profitability in Intensive Care Unit
|
||
| Terminated |
NCT01734694 -
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
|
Phase 4 | |
| Completed |
NCT01179022 -
Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions
|
N/A | |
| Recruiting |
NCT00404625 -
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
|
N/A | |
| Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 |